| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Université Montpellier 1, Centre d'études d'agents Pathogènes et Biotechnologies pour la Santé (CPBS), Montpellier, France
2 CNRS, UMR 5236, CPBS, 4 Bd Henri IV, CS 69033, F-34965 Montpellier, France
3 Université Montpellier 2, CPBS, F-34095 Montpellier, France
4 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia, Via A. Bianchi 7, 25124 Brescia, Italy
5 Department of Chemistry, Bates College, Lewiston, ME 04240, USA
Correspondence
Patrick Eldin
patrick.eldin{at}univ-montp1.fr
Nadir Mechti
nadir.mechti{at}univ-montp1.fr
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Published online ahead of print on 27 November 2008 as DOI 10.1099/vir.0.006288-0.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). Encephalomyocarditis virus (EMCV) is the prototype of the cardiovirus subgroup of picornaviruses. Its genome consists of a single-strand of messenger-sense RNA. Viral proteins are expressed from a large open reading frame encoding a giant precursor polyprotein (approx. 255 kDa), which is processed through a series of proteolytic cleavages to produce both capsid and non-structural proteins (Palmenberg, 1990). The majority of the processing reactions are carried out by the 3C protease (3CPRO), which acts both inter- and intramolecularly to produce polyprotein precursors as well as the mature 3CPRO polypeptide (Palmenberg et al., 1979). Cleavage of the polyprotein normally occurs between glutamine–glycine or glutamine–serine amino acid pairs, which are usually flanked by proline residues (Palmenberg et al., 1984). Besides its commitment to the processing of the viral polyprotein, picornaviral 3CPRO can also facilitate virus replication by altering fundamental cellular processes such as transcription and translation of host cell mRNA (Barral et al., 2007; Ehrenfeld, 1982; Kuyumcu-Martinez et al., 2004; Neznanov et al., 2005; Shen et al., 1996; Yalamanchili et al., 1996, 1997). Because the regulated proteolysis mediated by 3CPRO is a critical feature in both the processing of picornaviral polyprotein and the inhibition of cellular defences, 3CPRO constitutes an important target for host antiviral innate pathways. Consistent with this, the degradation of EMCV 3CPRO by the ubiquitin/26S proteasome system has been reported (Losick et al., 2003; Schlax et al., 2007). Although the precise role of this degradation during virus replication is still unknown, a possible role in the prevention of premature cell death or in the host antiviral defence has been proposed (Losick et al., 2003). Ubiquitin-dependent degradation of the 3CPRO was reported to be mediated in part by the E3
/Ubr1, E3 ubiquitin ligase, in conjunction with the isoform of E2 ubiquitin-conjugating enzyme UbcH1 (Glickman & Ciechanover, 2002; Lawson et al., 2001). However, EMCV 3CPRO has also been shown as a substrate for a UbcH5a-dependent pathway (Lawson et al., 1999) mediated by an unknown E3 ligase. Altogether, these data strongly suggest that the enhancement of 3CPRO degradation by the activation of alternative pathways of ubiquitination, involving different E2 enzymes and E3 ligases, may be part of the host antiviral response induced by interferon (IFN) against picornavirus infection.
Recently, many tripartite motif (TRIM) proteins have emerged as IFN-induced proteins involved in various cellular processes, including cell proliferation and antiviral activities (Meroni & Diez-Roux, 2005; Nisole et al., 2005). TRIM proteins contain several structurally related domains, including a cluster of highly conserved RING-finger domain, one or two B-box domains and a predicted coiled-coil region (Meroni & Diez-Roux, 2005). The RING-finger domain of several TRIM proteins has been shown to possess an E3 ubiquitin ligase activity that governs a cascade of ubiquitin transfer reactions to specific proteins leading to tight control of the concentration or the subcellular location of cellular target proteins (Gack et al., 2007; Kallijarvi et al., 2005; Kong et al., 2007; Kudryashova et al., 2005). The coiled-coil domain is described as a folding motif important for self-association and oligomerization (Meroni & Diez-Roux, 2005). In addition, some TRIM proteins contain a C-terminal SPRY domain proposed to be involved in protein–protein interactions and RNA binding (Hilton et al., 1998; Ponting et al., 1997). TRIM22 (also known as Staf50) was first identified to be an IFN-induced human protein that represses transcription directed by the long terminal repeat (LTR) promoter region of human immunodeficiency virus type 1 (HIV-1) (Tissot & Mechti, 1995). Recently, TRIM22 has been reported to be a natural antiviral effector of both HIV-1 replication and particle production (Barr et al., 2008; Bouazzaoui et al., 2006). The effect of TRIM22 was abolished by mutation of amino acids Cys15 and Cys18 of its RING-finger domain, suggesting that functional ubiquitin ligase activity is required for TRIM22-mediated antiviral activities. In addition to antiviral properties, TRIM22 has also been shown to be a p53 target gene involved in the control of proliferation of myeloid cells and implicated in haematopoietic and T-cell differentiation (Gongora et al., 2000; Obad et al., 2004, 2007a, b).
In this study, we analysed the involvement of TRIM22 in the innate antiviral immune response against picornaviruses. We reported that TRIM22 is an E3 ubiquitin ligase whose expression leads to noticeable antiviral effects towards EMCV infection in HeLa cells. This effect is dependent on its E3 ligase activity through ubiquitination of the viral 3CPRO. Altogether, our findings demonstrate that TRIM22 E3 ubiquitin ligase activity represents a new antiviral pathway in the mechanism of antiviral defence induced by IFN against picornaviruses.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Virus stocks and virus yield assays.
EMCV was prepared from supernatants of virus-infected L929 cells. Infected cells were then frozen and thawed three times. The supernatants were serially diluted, and the virus titres were measured alternatively by a plaque assay on L929 cells as previously described (Blondel et al., 1988) or by the end-point method (Milhaud et al., 1983).
Plasmid constructs.
TRIM22 constructs were derived by PCR amplification using pCMV-SPORT6-TRIM22 (IMAGE consortium; Open Biosystems). The inserts to construct p3XFlag-TRIM22, p3XFlag-TRIM22
RING, p3XFlag-TRIM22Nter and p3XFlag-TRIM22Cter expression vectors were generated by PCR amplification using PfuUltra DNA polymerase (Stratagene) with specific primers carrying HindIII and SalI sites, and subsequently cloned into the HindIII and SalI sites of p3XFlag-myc-CMV-24 expression vector (Sigma Aldrich). The EMCV 3CPRO expression vector was derived by PCR amplification from pEC9 plasmid encoding the whole EMCV genome and cloned into pcDNA3.1myc-his vector (Invitrogen). The nucleotide sequence of all the constructs was confirmed by DNA sequencing (GenomeExpress). The plasmid pMT123 driving the expression of HA-tagged 8x ubiquitin [HA-(Ub)8] was a generous gift from D. Bohmann (Rochester, New York, USA). The expression vectors for His-ubi and His-ubiK7R were a generous gift from M. T. Burgering (Utrecht, The Netherlands). pEC9 plasmid was a generous gift from A. Palmenberg (Madison, Wisconsin, USA).
Antibodies.
Polyclonal anti-EMCV-3CPRO antibodies were prepared and purified as previously described (Lawson et al., 1994). Mouse monoclonal antibodies directed against EMCV capsid protein VP1 were prepared as previously described (Borrego et al., 2002). Anti-Flag monoclonal and polyclonal antibodies, anti--tubulin monoclonal antibody, peroxidase-conjugated anti-mouse and anti-rabbit IgG (whole molecule) secondary antibodies were purchased from Sigma Aldrich. Anti-HA 12CA5 mouse monoclonal antibody was purchased from Roche Diagnostic and anti-ubiquitin antibody was purchased from Santa Cruz Biotechnology.
Immunoprecipitation and protein analysis.
HeLa or HEK293T cells were resuspended in lysis buffer consisting of PBS buffer containing 1 % NP-40, 1 mM DTT, 100 µM PMSF and protease inhibitor cocktail (1 tablet per 10 ml; Roche Diagnostics). Supernatant (10 000 g) was prepared and used for immunoprecipitation. The extracts were incubated for 1 h at 4 °C with specific antibodies bound to sheep anti-mouse or anti-rabbit IgG-coupled magnetic beads (Dynabeads; Invitrogen). The beads were washed five times in lysis buffer. The immunoprecipitated proteins were resuspended in 20 µl loading buffer [10 mM Tris/HCl pH 6.8, 1 % SDS, 5 mM EDTA and 50 % glycerol (v/v)], incubated for 5 min at 95 °C, fractionated by SDS-PAGE and transferred onto PVDF membranes. After a blocking step, the membranes were incubated with the appropriate antibody and then developed using an enhanced chemiluminescent detection system (ECL+Plus; Amersham Pharmacia Biotech). For Ni–NTA (Qiagen) pull-down experiments, the cells were lysed in denaturing buffer (6 M guanidine/HCl, 100 mM Na2HPO4/NaH2PO4 at pH 8.0, 10 mM Tris/HCl at pH 8.0, 0.2 % Triton X-100) and ubiquitinated proteins were precipitated using Ni–NTA agarose.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Kallijarvi et al., 2005; Kong et al., 2007; Kudryashova et al., 2005). This occurs through a three-step process involving ubiquitin activating (E1) and ubiquitin-conjugating (E2) enzymes constitutively expressed in the cells and an ubiquitin E3 ligase that catalyses direct transfer of the activated ubiquitin from E2- to E3-bound substrates thereby providing the specificity for the target proteins. To determine whether the RING-finger domain of TRIM22 can confer to its ubiquitin ligase activity, Flag–TRIM22 fusion protein and HA-tagged ubiquitin polypeptide (HA-ubi) were co-expressed in HeLa cells. Subsequently, whole-cell extracts were prepared and analysed by immunoblotting with anti-HA monoclonal antibodies in order to detect HA-tagged ubiquitin conjugated proteins. As shown in Fig. 1(b), ubiquitin conjugates were produced in cells transfected with HA-ubi alone, reflecting ubiquitination by endogenous ubiquitin ligating enzymes. The level of conjugates was markedly greater in the presence of Flag–TRIM22. The presence of a high-molecular-mass smear of ubiquitinated proteins demonstrates that TRIM22 engenders robust ubiquitination in HeLa cells. The levels of Flag–TRIM22 were monitored by probing the membrane with anti-Flag antibody (Fig. 1b). Extracts from cells expressing Flag–TRIM22 or HA-ubi alone, used as negative controls, contained much smaller quantities of ubiquitin–protein conjugates. To evaluate the implication of the RING-finger domain in the ubiquitin-conjugating activity of TRIM22, we constructed an expression vector for expressing a TRIM22 version deleted of the first 59 aa residues corresponding to the RING-finger domain (Fig. 1a). HA-ubi was co-expressed with Flag–TRIM22RING and the ubiquitin-conjugated proteins were analysed as previously described. As expected, no ubiquitination activity was detected with TRIM22RING as compared with the wild-type TRIM22 (Fig. 1b, upper panel), whereas both proteins were expressed at the same level (Fig. 1b, lower panel). These data strongly suggest that TRIM22 is an ubiquitin E3 ligase that catalyses ubiquitin-conjugation of cellular proteins and that the RING-finger domain is required for its activity.
|
). His-ubiquitin (His-ubi) was co-expressed with Flag–TRIM22, Flag–TRIM22Cter or Flag–TRIM22Nter in HEK293T cells. Cells were collected (10 %) and whole-cell extracts were analysed by Western blotting using anti-Flag antibodies (Fig. 2b). In the presence of His-ubi, additional high-molecular-mass bands were revealed with Flag–TRIM22 and Flag–TRIM22Nter, suggesting that Flag–TRIM22 and the RING-finger domain of TRIM22 are ubiquitinated. Subsequently, the remaining 90 % of cells were lysed in a denaturing buffer containing 6 M guanidine/HCl to dissociate ubiquitinated proteins bound to Flag–TRIM22, and ubiquitinated proteins were precipitated using Ni–NTA beads and analysed at first by 8 % SDS-PAGE to resolve high-molecular-mass ubiquitin-conjugated TRIM22 products. Western blot detection using anti-Flag antibodies indicated that TRIM22 was polyubiquitinated (Fig. 2c). To resolve low-molecular-mass products, such as ubiquitinated TRIM22Nter, the three last samples shown in Fig. 2(c) were reanalysed by 12 % SDS-PAGE. Western blot detection using anti-Flag antibodies revealed that the TRIM22 RING-finger domain (Flag–TRIM22Nter) appeared to be conjugated to one ubiquitin molecule at only one site (Fig. 2d). As an analysis of the TRIM22 amino acid sequence revealed the presence of 37 lysine residues, our finding may reflect the ability of TRIM22 to be polyubiquitinated in one or a few residues or to be monoubiquitinated in many residues. To evaluate these two possibilities, we used an His-ubiquitin construct (His-ubiK7R) that undergoes only monoubiquitination because all seven lysine residues of ubiquitin have been mutated to arginines (van der Horst et al., 2006). Ni–NTA pull-down assays using this modified His-ubi resulted in a pattern of two prominent ubiquitinated forms of Flag–TRIM22 with relative molecular masses corresponding to the molecular mass of Flag–TRIM22 plus approximately 8000 or 16 000 Da (Fig. 2e). These data indicated that TRIM22 is essentially ubiquitinated at two major sites and undergoes mono- and polyubiquitination.
|
) consistent with 3CPRO ubiquitination by endogenous ubiquitin and ubiquitin ligases, as previously described (Lawson et al., 1994; Schlax et al., 2007). When 3CPRO was co-expressed with His-ubi, the intensity of the bands was enhanced and a slight decrease in their apparent mobility, due to the His-tag present on the transfected His-ubi, was observed. Interestingly, Flag–TRIM22 expression was associated with a significant and noticeable increase in 3CPRO ubiquitination, in both the presence and the absence of His-ubi. These data demonstrate that TRIM22 expression enhances 3CPRO ubiquitination in intact cells.
|
, 3CPRO was strongly co-precipitated with Flag–TRIM22 and Flag–TRIM22Cter. No co-precipitation was detectable with extracts from Flag–TRIM22Nter or Flag–IM25 expressing HeLa cells. No co-precipitation was also observed with extract from cells tranfected with the p3XFlag empty vector (data not shown). These data demonstrate that the C-terminal domain of TRIM22 can tightly associate with 3CPRO. Because ubiquitin-protein ligases must recognize and bind to their substrates, the enhancement of 3CPRO ubiquitination by TRIM22 suggests that TRIM22 may function as an E3 ligase in the 3CPRO ubiquitination process.
|
). The results of a typical experiment, presented in Fig. 5, show that the cells transfected with the wild-type Flag–TRIM22 expressing construct exhibited a significant reduction in virus protein expression as compared with cells transfected with the empty p3XFlag vector. No protective effect was observed in HeLa cells expressing either Flag–TRIM22Cter or Flag–TRIM22Nter, suggesting that TRIM22 antiviral activity was mediated through its ubiquitin ligase activity. Similar results were obtained in three independent experiments.
|
). Virus titres were then measured using the end-point method with L929 cells. TRIM22 clearly induces an antiviral state that leads to a 4.6- (T7) or 2.9 (T8)-fold reduction in viral charge. According to the data presented in Fig. 5
, the fact that TRIM22Nter and TRIM22Cter deletion mutants did not exhibit any antiviral effects, strongly suggested that TRIM22 antiviral effect is dependent on both the integrity of its E3 ligase activity (TRIM22Nter) and of its ability to interact with 3CPRO (TRIM22Cter).
|
). 3CPRO and 3CD appeared 6 h post-infection in normal cells and remained barely detectable in Flag–TRIM22 expressing cells. Altogether, our data obtained either on transiently TRIM22-transfected HeLa cells or in HeLa cells constitutively expressing TRIM22, highlight the TRIM22-mediated antiviral effects against EMCV infection. Our data also suggest that these effects are clearly dependent on TRIM22 E3 ligase integrity, and that they could be in part mediated by TRIM22-dependent ubiquitination of the viral 3C protease.
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Samuel, 2001). The huge diversity of virus families and the fact that viruses have developed strategies to circumvent the antiviral activities of IFN imply that mammalian cells use various alternative strategies to interfere with viral multiplication. Many E3 ubiquitin ligase members of the TRIM family are inducible by IFNs, providing candidate mediators for the IFN-induced antiviral state (Nisole et al., 2005). Some recent studies have highlighted the role of ubiquitin ligases in both innate and adaptive immunity, as well as in immune evasion (for review see Liu, 2004). In this report, we provide evidence that TRIM22 E3 ubiquitin ligase activity participates in a novel antiviral pathway as part of the mechanism of IFN action against picornaviruses.
We demonstrate a crucial role for the RING-finger domain in TRIM22 ubiquitin E3 ligase activity. Indeed, ubiquitin ligase activity of a TRIM22 mutant lacking the RING-finger domain (TRIM22RING) was strongly reduced in comparison with the wild-type TRIM22. These data are consistent with other E3 ligases of the TRIM family, where the RING-finger domain has been shown to mediate the interaction with E2 ubiquitin-conjugating enzymes (Meroni & Diez-Roux, 2005). As described for other E3 ubiquitin ligases, TRIM22 is ubiquitinated, an event that may be relevant to its regulation. According to our data, pending submission of our manuscript, TRIM22 has been reported to be a novel RING-finger E3 ubiquitin ligase (Duan et al., 2008). In that study, using GST–TRIM22 purified from GST–TRIM22 transfected COS cells as E3 source, the authors found that TRIM22 underwent self-ubiquitination in combination with the E2 enzyme UbcH5b, in an in vitro ubiquitination assay. In addition, because polyubiquitinated forms of TRIM22 seemed stabilized by proteasome inhibitor the authors concluded that TRIM22 targets itself for proteosomal degradation. However, polyubiquitination of proteins normally results in proteasome-mediated protein degradation, whereas monoubiquitination may mediate signalling functions (reviewed by Sigismund et al., 2004). As the described stabilization of TRIM22 appeared only very partial, these data suggested that at least part of TRIM22 ubiquitination could participate to the regulation of its activity. In accordance with this hypothesis, we found that TRIM22 is likely ubiquitinated at two major sites. One site located in the RING-finger region undergoes monoubiquitination. As RING-finger ubiquitin E3 ligase-mediated ubiquitination occurs through a multi-step process involving binding of ubiquitin-conjugating (E2) enzymes to the RING-finger domain of the E3, this monoubiquitination might be involved in TRIM22 regulation by modulating the E2–E3 interaction. The second site, located in the C-terminal region, undergoes polyubiquitination that might be involved in the control of TRIM22 stability or interaction with substrate proteins. This possibility is supported by the observation that the RING-finger region was ubiquitinated, while having lost the ability to catalyse the ubiquitination of other substrate proteins. This suggests that the TRIM22 C-terminal structurally related coiled-coil and SPRY domains are required for protein substrate recognition. Interestingly, the fact that Flag–TRIM22Cter which has lost the RING-finger-mediated ubiquitin ligase activity was not ubiquitinated suggests that TRIM22 ubiquitination was the result of autoubiquitination and not ubiquitination by other constitutively expressed ubiquitin ligases present in the cell extracts. Altogether, our data clearly demonstrate that TRIM22 is a RING-finger E3 ubiquitin ligase.
We demonstrated that stable and constitutive expression of TRIM22 confers a significant protection against EMCV infection in HeLa cells, providing a new antiviral pathway against picornaviruses. The same experiments were performed in transiently transfected cells, demonstrating that the protective effect was due to TRIM22 expression and was not a characteristic of the selected clones. In host cells, during virus infection the destruction of the short-lived picornaviral 3CPRO is mediated by the ubiquitin/26S proteasome system (Losick et al., 2003; Schlax et al., 2007). Although the precise role of 3CPRO degradation is still unknown, we proposed its involvement in the host antiviral response. Consistent with this hypothesis, in this study we found that TRIM22 specifically interacts with 3CPRO and that 3CPRO ubiquitination can be enhanced by TRIM22 in HeLa cells. We demonstrated that functional TRIM22 E3 ligase is required for TRIM22-mediated antiviral activity against EMCV infection. Indeed, the mutant of TRIM22 lacking the RING-finger domain and the ubiquitin ligase activity did not interfere with virus replication. In addition, the N-terminal region of TRIM22 did not exhibit antiviral effects, suggesting that the coiled-coil and SPRY domains are required for TRIM22–protein substrate recognition, as described for some E3 ligases (Meroni & Diez-Roux, 2005). Accordingly, we found that the C-terminal, but not the N-terminal region of TRIM22, can bind 3CPRO. These data strongly support the idea that TRIM22 antiviral activity is mediated through the ubiquitination of the viral protease. However, we cannot totally exclude that TRIM22 could mediate 3CPRO ubiquitination through the activation of other cellular E3 ligase activities. As TRIM E3 ligases are known to form homo- and heterodimers, TRIM22 may also act by mediating 3CPRO recognition by unknown TRIM E3 ligases. Indeed, 3CPRO has been shown to be ubiquitinated through several different ubiquitinating pathways, not only by Ubr1. Lawson et al. (1999) published data that showed that both Ubr1- and a UbcH5a-dependent unknown E3 ligases target EMCV 3CPRO. In addition, the existence of other unidentified E3 ligases targeting 3CPRO ubiquitination can not be excluded. Duan et al. (2008) reported that TRIM22 E3 ligase activity was dependent on UbcH5b as an E2 partner. Because UbcH5a and UbcH5b are functionally homologous, we can hypothesize that the unknown E3 ligase may be TRIM22. Additional experiments are required to clarify this point and to clearly demonstrate whether or not the direct conjugation of ubiquitin to 3CPRO by TRIM22 E3 ligase activity is involved in the TRIM22-mediated antiviral activity against EMCV infection.
Although E3 ubiquitin ligases are involved in non-lysosomal protein degradation, many studies point to the involvement of some ligases in many facets of cell biology unrelated to proteolysis, including transcription and trafficking (Ben-Neriah, 2002; Sigismund et al., 2004; Woelk et al., 2007). In general, polyubiquitination of proteins results in proteasome-mediated protein degradation, whereas monoubiquitination may mediate other regulating functions (Ben-Neriah, 2002). Surprisingly, we found that TRIM22 expression was associated with an increase of 3CPRO ubiquitination in HeLa cells with a pattern corresponding to the addition of one to three ubiquitin molecules, suggesting that TRIM22 mediates the monoubiquitination of the viral protein rather than polyubiquitination. The precise identification of 3CPRO-binding sites on TRIM22 and of the exact 3CPRO amino acid residues involved in ubiquitin conjugation will greatly enhance our understanding of the antiviral effects mediated by TRIM22 against EMCV. On the basis of these observations, it is reasonable to speculate that TRIM22 antiviral activity can be mediated through limited 3CPRO ubiquitination, resulting in altered proteinase function or subcellular localization rather than in proteasome-mediated degradation. Several forms of 3CPRO are synthesized during virus replication because picornaviral polyproteins are cleaved sequentially through a series of intermediates (Hall & Palmenberg, 1996). Thus, it will be very interesting to evaluate whether these different 3CPRO containing polyproteins can serve as substrates for TRIM22-catalysed ubiquitination.
TRIM22 also exhibits antiviral properties against other RNA viruses. TRIM22 has been shown to interfere with HIV-1 infection by either LTR promoter repression (Tissot & Mechti, 1995), inhibition of viral replication (Bouazzaoui et al., 2006) or reduction of particle production (Barr et al., 2008). Interestingly, the C-terminal SPRY domain of TRIM proteins is proposed to be involved in protein–protein interactions and RNA binding (Hilton et al., 1998; Ponting et al., 1997). So, it is tempting to speculate that RNA genomic viruses might be preferential targets for TRIM22 antiviral activity. The SPRY domain of TRIM22 might be required for sensing viral RNAs and promoting ubiquitination of viral proteins. Obviously, further studies are needed to test TRIM22 antiviral activity against other families of RNA viruses and to clarify the exact mechanism by which TRIM22 elicits its antiviral effects. These studies will lead to the identification of a set of new cellular or viral TRIM22 substrates that could be new targets for TRIM22-mediated ubiquitin conjugation.
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Barral, P. M., Morrison, J. M., Drahos, J., Gupta, P., Sarkar, D., Fisher, P. B. & Racaniello, V. R. (2007). MDA-5 is cleaved in poliovirus-infected cells. J Virol 81, 3677–3684.
Ben-Neriah, Y. (2002). Regulatory functions of ubiquitination in the immune system. Nat Immunol 3, 20–26.[CrossRef][Medline]
Blondel, D., Petitjean, A. M., Dezelee, S. & Wyers, F. (1988). Vesicular stomatitis virus in Drosophila melanogaster cells: regulation of viral transcription and replication. J Virol 62, 277–284.
Borrego, B., Garcia-Ranea, J. A., Douglas, A. & Brocchi, E. (2002). Mapping of linear epitopes on the capsid proteins of swine vesicular disease virus using monoclonal antibodies. J Gen Virol 83, 1387–1395.
Bouazzaoui, A., Kreutz, M., Eisert, V., Dinauer, N., Heinzelmann, A., Hallenberger, S., Strayle, J., Walker, R., Rubsamen-Waigmann, H. & other authors (2006). Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages. Virology 356, 79–94.[CrossRef][Medline]
Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. (1998). Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95, 15623–15628.
Duan, Z., Gao, B., Xu, W. & Xiong, S. (2008). Identification of TRIM22 as a RING finger E3 ubiquitin ligase. Biochem Biophys Res Commun 374, 502–506.[CrossRef][Medline]
Ehrenfeld, E. (1982). Poliovirus-induced inhibition of host-cell protein synthesis. Cell 28, 435–436.[CrossRef][Medline]
Gack, M. U., Shin, Y. C., Joo, C. H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z. & other authors (2007). TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916–920.[CrossRef][Medline]
Glickman, M. H. & Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82, 373–428.
Gongora, C., Tissot, C., Cerdan, C. & Mechti, N. (2000). The interferon-inducible Staf50 gene is downregulated during T cell costimulation by CD2 and CD28. J Interferon Cytokine Res 20, 955–961.[CrossRef][Medline]
Hall, D. J. & Palmenberg, A. C. (1996). Mengo virus 3C proteinase: recombinant expression, intergenus substrate cleavage and localization in vivo. Virus Genes 13, 99–110.[Medline]
Hilton, D. J., Richardson, R. T., Alexander, W. S., Viney, E. M., Willson, T. A., Sprigg, N. S., Starr, R., Nicholson, S. E., Metcalf, D. & Nicola, N. A. (1998). Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A 95, 114–119.
Kallijarvi, J., Lahtinen, U., Hamalainen, R., Lipsanen-Nyman, M., Palvimo, J. J. & Lehesjoki, A. E. (2005). TRIM37 defective in mulibrey nanism is a novel RING finger ubiquitin E3 ligase. Exp Cell Res 308, 146–155.[CrossRef][Medline]
Kong, H. J., Anderson, D. E., Lee, C. H., Jang, M. K., Tamura, T., Tailor, P., Cho, H. K., Cheong, J., Xiong, H. & other authors (2007). Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol 179, 26–30.
Kudryashova, E., Kudryashov, D., Kramerova, I. & Spencer, M. J. (2005). Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. J Mol Biol 354, 413–424.[CrossRef][Medline]
Kuyumcu-Martinez, N. M., Van Eden, M. E., Younan, P. & Lloyd, R. E. (2004). Cleavage of poly(A)-binding protein by poliovirus 3C protease inhibits host cell translation: a novel mechanism for host translation shutoff. Mol Cell Biol 24, 1779–1790.
Lawson, T. G., Gronros, D. L., Werner, J. A., Wey, A. C., DiGeorge, A. M., Lockhart, J. L., Wilson, J. W. & Wintrode, P. L. (1994). The encephalomyocarditis virus 3C protease is a substrate for the ubiquitin-mediated proteolytic system. J Biol Chem 269, 28429–28435.
Lawson, T. G., Gronros, D. L., Evans, P. E., Bastien, M. C., Michalewich, K. M., Clark, J. K., Edmonds, J. H., Graber, K. H., Werner, J. A. & other authors (1999). Identification and characterization of a protein destruction signal in the encephalomyocarditis virus 3C protease. J Biol Chem 274, 9904–9980.[Medline]
Lawson, T. G., Sweep, M. E., Schlax, P. E., Bohnsack, R. N. & Haas, A. L. (2001). Kinetic analysis of the conjugation of ubiquitin to picornavirus 3C proteases catalyzed by the mammalian ubiquitin-protein ligase E3. J Biol Chem 276, 39629–39637.
Liu, Y. C. (2004). Ubiquitin ligases and the immune response. Annu Rev Immunol 22, 81–127.[CrossRef][Medline]
Losick, V. P., Schlax, P. E., Emmons, R. A. & Lawson, T. G. (2003). Signals in hepatitis A virus P3 region proteins recognized by the ubiquitin-mediated proteolytic system. Virology 309, 306–319.[CrossRef][Medline]
Meroni, G. & Diez-Roux, G. (2005). TRIM/RBCC, a novel class of ‘single protein RING finger’ E3 ubiquitin ligases. Bioessays 27, 1147–1157.[CrossRef][Medline]
Milhaud, P. G., Silhol, M., Faure, T. & Milhaud, X. (1983). Numerical tables for the direct estimation of virus titres by the maximum-likelihood method. Ann Virol E134, 405–416.
Neznanov, N., Chumakov, K. M., Neznanova, L., Almasan, A., Banerjee, A. K. & Gudkov, A. V. (2005). Proteolytic cleavage of the p65-RelA subunit of NF-
B during poliovirus infection. J Biol Chem 280, 24153–24158.
Nisole, S., Stoye, J. P. & Saib, A. (2005). TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3, 799–808.[CrossRef][Medline]
Obad, S., Brunnstrom, H., Vallon-Christersson, J., Borg, A., Drott, K. & Gullberg, U. (2004). Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene 23, 4050–4059.[CrossRef][Medline]
Obad, S., Olofsson, T., Mechti, N., Gullberg, U. & Drott, K. (2007a). Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow. Leuk Res 31, 995–1001.[CrossRef][Medline]
Obad, S., Olofsson, T., Mechti, N., Gullberg, U. & Drott, K. (2007b). Regulation of the interferon-inducible p53 target gene TRIM22 (Staf50) in human T lymphocyte activation. J Interferon Cytokine Res 27, 857–864.[CrossRef][Medline]
Palmenberg, A. C. (1990). Proteolytic processing of picornaviral polyprotein. Annu Rev Microbiol 44, 603–623.[CrossRef][Medline]
Palmenberg, A. C., Pallansch, M. A. & Rueckert, R. R. (1979). Protease required for processing picornaviral coat protein resides in the viral replicase gene. J Virol 32, 770–778.
Palmenberg, A. C., Kirby, E. M., Janda, M. R., Drake, N. L., Duke, G. M., Potratz, K. F. & Collett, M. S. (1984). The nucleotide and deduced amino acid sequences of the encephalomyocarditis viral polyprotein coding region. Nucleic Acids Res 12, 2969–2985.
Ponting, C., Schultz, J. & Bork, P. (1997). SPRY domains in ryanodine receptors (Ca2+-release channels). Trends Biochem Sci 22, 193–194.[CrossRef][Medline]
Samuel, C. E. (2001). Antiviral actions of interferons. Clin Microbiol Rev 14, 778–809.
Schlax, P. E., Zhang, J., Lewis, E., Planchart, A. & Lawson, T. G. (2007). Degradation of the encephalomyocarditis virus and hepatitis A virus 3C proteases by the ubiquitin/26S proteasome system in vivo. Virology 360, 350–363.[CrossRef][Medline]
Shen, Y., Igo, M., Yalamanchili, P., Berk, A. J. & Dasgupta, A. (1996). DNA binding domain and subunit interactions of transcription factor IIIC revealed by dissection with poliovirus 3C protease. Mol Cell Biol 16, 4163–4171.[Abstract]
Sigismund, S., Polo, S. & Di Fiore, P. P. (2004). Signaling through monoubiquitination. Curr Top Microbiol Immunol 286, 149–185.[Medline]
Tissot, C. & Mechti, N. (1995). Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem 270, 14891–14898.
van der Horst, A., de Vries-Smits, A. M., Brenkman, A. B., van Triest, M. H., van den Broek, N., Colland, F., Maurice, M. M. & Burgering, B. M. (2006). FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 8, 1064–1073.[CrossRef][Medline]
Whitton, J. L., Cornell, C. T. & Feuer, R. (2005). Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol 3, 765–776.[CrossRef][Medline]
Woelk, T., Sigismund, S., Penengo, L. & Polo, S. (2007). The ubiquitination code: a signalling problem. Cell Div 2, 11[CrossRef][Medline]
Yalamanchili, P., Harris, K., Wimmer, E. & Dasgupta, A. (1996). Inhibition of basal transcription by poliovirus: a virus-encoded protease (3Cpro) inhibits formation of TBP-TATA box complex in vitro. J Virol 70, 2922–2929.[Abstract]
Yalamanchili, P., Datta, U. & Dasgupta, A. (1997). Inhibition of host cell transcription by poliovirus: cleavage of transcription factor CREB by poliovirus-encoded protease 3Cpro. J Virol 71, 1220–1226.[Abstract]
Received 5 August 2008;
accepted 9 November 2008.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
